Evidence map›Paper›PMID 25411577›Full record

ArticleAdvanced functional materials2014

High Throughput, Polymeric Aqueous Two-Phase Printing of Tumor Spheroids.

Ehsan Atefi, Stephanie Lemmo, Darcy Fyffe, Gary D Luker, Hossein Tavana

Abstract read
In one paragraph

Article in Advanced functional materials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Reconstructing the tumor architecture into organoids.Advanced drug delivery reviews · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Three-dimensional models of breast cancer-fibroblasts interactions.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ehsan AtefiDepartment of Biomedical Engineering, The University of Akron, Akron, OH 44325 USA.
Stephanie LemmoDepartment of Biomedical Engineering, The University of Akron, Akron, OH 44325 USA.
Darcy FyffeDepartment of Biomedical Engineering, The University of Akron, Akron, OH 44325 USA.
Gary D LukerDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105 USA ; Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48105 USA ; Biomedical Engineering, University of Michigan, Ann Arbor, MI 48105 USA.
Hossein TavanaDepartment of Biomedical Engineering, The University of Akron, Akron, OH 44325 USA.

Funding

A Novel High Throughput Tumor Spheroid MicrotechnologyR21CA182333 · NCI · UNIVERSITY OF AKRON · PI LUKER, GARY D, TAVANA, HOSSEIN · 2013 to 2014
$503k
NCI NIH HHS R21 CA182333
6 · The paper itself

Abstract

This paper presents a new 3D culture microtechnology for high throughput production of tumor spheroids and validates its utility for screening anti-cancer drugs. We use two immiscible polymeric aqueous solutions and microprint a submicroliter drop of the "patterning" phase containing cells into a bath of the "immersion" phase. Selecting proper formulations of biphasic systems using a panel of biocompatible polymers results in the formation of a round drop that confines cells to facilitate spontaneous formation of a spheroid without any external stimuli. Adapting this approach to robotic tools enables straightforward generation and maintenance of spheroids of well-defined size in standard microwell plates and biochemical analysis of spheroids

Indexed as

3D cultureAqueous two-phase systemDrug screeningHigh throughputTumor Spheroid

Identifiers

PMID25411577
PMCPMC4233147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.